홈 › 급성 골수성 백혈병 › 코네티컷 › New Haven
CT New Haven의 급성 골수성 백혈병 임상 시험
급성 골수성 백혈병 관련 연구 17개가 New Haven 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
피험자 모집 중2상
- Yale University, New Haven
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven · 3마일 거리
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
피험자 모집 중1상
- Yale University, New Haven
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
피험자 모집 중2상
- Yale University, New Haven
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
피험자 모집 중2상
- Yale University, New Haven
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
피험자 모집 중2상
- Yale University, New Haven
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven · 3마일 거리
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
피험자 모집 중3상
- Yale University, New Haven
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
피험자 모집 중1/2상
- Yale University, New Haven
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
피험자 모집 중3상
- Yale University, New Haven
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
피험자 모집 중3상
- Yale University School of Medicine, New Haven
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
피험자 모집 중1상
- Smilow Cancer Hospital at Yale New Haven, New Haven
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
피험자 모집 중1상
- Yale University, Yale Cancer Center, New Haven
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
피험자 모집 중관찰 연구
- Yale New Haven Hospital, New Haven
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
피험자 모집 중1상
- Yale New Haven Hospital, New Haven
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
피험자 모집 중2/3상
- Yale University, New Haven
Revumenib in Combination With 7+3 + Midostaurin in AML
피험자 모집 중1상
- Yale Cancer Center, New Haven
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
피험자 모집 중1상
- Yale Cancer Center and Smilow Cancer Hospital, New Haven
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
피험자 모집 중1/2상
- Yale University, New Haven
다른 도시의 급성 골수성 백혈병 시험
- Houston, TX연구 85개
- New York City, NY연구 51개
- Boston, MA연구 44개
- Seattle, WA연구 41개
- Baldwin Park, CA연구 40개
- Columbus, OH연구 35개
- Philadelphia, PA연구 34개
- Durham, NC연구 33개
- Atlanta, GA연구 31개
- Tampa, FL연구 29개
- Chicago, IL연구 26개
- Portland, OR연구 25개
New Haven의 다른 연구
- 비소세포폐암연구 41개
- 유방암연구 38개
- 암 (전체)연구 33개
- 전이성 암연구 23개
- 폐암연구 22개
- 두경부 편평세포암연구 22개
- 난소암연구 21개
- 대장직장암연구 20개
- 전립선암연구 20개
- 알코올 사용 장애(AUD)연구 17개
- 오피오이드 과다 복용연구 17개
- 췌장암연구 16개
ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.